AbCellera to present Phase 1/2 data for menopause hot-flash drug ABCL635 at TMS 2026 meeting

PUBT · 1d ago
AbCellera to present Phase 1/2 data for menopause hot-flash drug ABCL635 at TMS 2026 meeting
  • AbCellera flagged Phase 1/2 findings for ABCL635, a non-hormonal antibody aimed at menopausal hot flashes.
  • Results have not been presented yet; data are scheduled for a poster at The Menopause Society’s 2026 annual meeting on Oct. 22.
  • Readout supports continued development, based on reported safety, drug exposure, biological activity, and early signs of symptom improvement.
  • The program targets NK3R, positioning ABCL635 as a long-acting approach in a competitive market for vasomotor symptom treatments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261008273252) on October 08, 2026, and is solely responsible for the information contained therein.